GSK signs ‘bubble boy disease’ agreement with MolMed

GlaxoSmithKline’s efforts to tackle a rare and often deadly immune deficiency are making progress following the announcement that they have signed a deal with Italy’s MolMed. In October last year, GSK linked up with San Raffaele Telethon Institute, gaining an exclusive licence to an investigational gene therapy for ADA-SCID (adenosine deaminase deficiency – severe combined

Continue Reading

GSK Expands Vaccine Presence in China

GlaxoSmithKline (GSK) has entered into an agreement to purchase Shenzhen Neptunus’ stake in a previously formed joint venture between the companies involved in the development and manufacture of influenza vaccines in China, Hong Kong, and Macau. GSK will pay Shenzhen Neptunus $39 million, after which GSK will be the sole owner of the joint venture

Continue Reading